
CLAIMS

1. Use of CuPTSM for the manufacture of a medicament for the treatment of amyotrophic lateral sclerosis (ALS) in a subject in need thereof, wherein the CuPTSM has the formula:



.

2. The use of claim 1, wherein the ALS is familial or sporadic.

3. The use of claim 1 or 2, wherein the subject in need thereof is treatment naïve.

4. The use of claim 1 or 2, wherein the subject in need thereof has received previous treatment for ALS.

5. The use of claim 1, wherein the therapeutically effective dose of CuPTSM is 0.01 mg/kg/day – 12 mg/kg/day.

6. The use of any of claims 1-5, wherein the subject in need thereof is human, and the human has a genetic mutation associated with ALS.

7. The use of claim 6, wherein the genetic mutation associated with ALS comprises a mutation in the SOD1 gene.

8. The use of any of claims 1-7, wherein the CuPTSM is to be administered to the subject in combination with an additional ALS treatment therapy.

9. The use of claim 8, wherein the CuPTSM is to be administered at a dose that achieves a plasma Cmax of about 50-640 ng/mL in the subject.

10. Use of a pharmaceutical composition comprising CuPTSM and a pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment of amyotrophic lateral sclerosis (ALS) in a subject in need thereof.

11. The use of claim 10, wherein the pharmaceutically acceptable excipient comprises cellulose and a surfactant.

12. The use of claim 11, wherein the cellulose is methylcellulose.

13. The use of claim 11, wherein the surfactant is a polysorbate.

14. The use of claim 13, wherein the polysorbate is TWEEN.

15. The use of claim 14, wherein the TWEEN is TWEEN-80.